TP53 and cancer: In TP53 or ATM-deficient CLL cells, cancer cells are dependent on the remaining ATR-CHK1 pathway for survival, and inhibition of ATR signaling by ATRi (AZD6738) leads to accumulation of unrepaired DNA damage and eventual death due to mitotic catastrophe [73, 74].